Brain Tumour Research

ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board

Retrieved on: 
Wednesday, September 1, 2021

September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.

Key Points: 
  • September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
  • Under Mr. Abbeys leadership, Argos Therapeutics successfully completed an IPO on NASDAQ, as well as a pivotal Phase 3 clinical trial in kidney cancer.
  • I am looking forward to working with the team at ImmunOs and its advisory boards, said Jeffrey Abbey, MBA, JD, COO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.

WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101

Retrieved on: 
Tuesday, March 16, 2021

VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (WPD or the Company) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma.

Key Points: 
  • VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (WPD or the Company) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to announce that it has engaged Paediatric Oncology expert, Prof. David Walker to support and develop preclinical and clinical programs for WPD101 in glioblastoma.
  • Prof. Walker has over 40 years of medical experience in Paediatric Oncology and is a world-renowned expert in brain cancer.
  • Currently, he is an Emeritus Professor of Paediatric Oncology, Childrens Brain Tumour Research Centre, at the University of Nottingham.
  • Prof. Walker will be advising WPD with strategic decisions related to the development of WPD101 in glioblastoma.

First Brain Tumour Registry for Canada Captures Real-World Patient Evidence

Retrieved on: 
Tuesday, May 14, 2019

Meningioma is the most common primary brain tumour in females, while glioblastoma is the most common primary tumour in males.2

Key Points: 
  • Meningioma is the most common primary brain tumour in females, while glioblastoma is the most common primary tumour in males.2
    TORONTO, May 14, 2019 /CNW/ - Brain Tumour Foundation of Canada is proud to launch the first-ever Brain Tumour Registry of Canada (BTRC) a surveillance research collaborative.
  • Brain Tumour Foundation of Canada identified the gap in available information on Canadian brain tumour patients and prioritized the development of a pan-Canadian surveillance report.
  • The Brain Tumour Registry of Canada ( BTRC ) has been established in 2019 to ensure that every brain tumour in Canada is counted.
  • About Brain Tumour Foundation of Canada:
    Brain Tumour Foundation of Canada is the only national charity offering information and support to patients affected by any kind of brain tumour be it cancerous, non-malignant or metastases.

Bunzl raises $55,000 for paediatric brain tumour research

Retrieved on: 
Friday, July 13, 2018

BURLINGTON, ON, July 13, 2018 /CNW/ - Bunzl Canada held its 19th annual golf tournament in support of the world's largest brain tumour research centre of its kind, the Arthur & Sonia Labatt Brain Tumour Research Centre at Toronto's Hospital for Sick Children.

Key Points: 
  • BURLINGTON, ON, July 13, 2018 /CNW/ - Bunzl Canada held its 19th annual golf tournament in support of the world's largest brain tumour research centre of its kind, the Arthur & Sonia Labatt Brain Tumour Research Centre at Toronto's Hospital for Sick Children.
  • This past year, the Research Centre published a major paper based on its research work related to the delivery of therapeutics to brain tumours across the blood brain barrier (BBB).
  • said Dr. James Rutka, Co-director & Principal Investigator at the Arthur & Sonia Labatt Brain Tumour Research Centre.
  • "I want to thank our great vendor partners here at Bunzl Canada who have been an integral part of us being able to support the Centre and its paediatric brain tumour research over the past 19 years."